FGF19 is an inclusion criterion in 3 clinical trials for malignant solid tumor, of which 2 are open and 1 is closed. Of the trials that contain FGF19 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 1/phase 2 (2 open) [4].

FGF19 is an inclusion criterion in 3 clinical trials for urothelial carcinoma, of which 3 are open and 0 are closed. Of the trials that contain FGF19 status and urothelial carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 1 is phase 2 (1 open) [4].

FGF19 is an inclusion criterion in 2 clinical trials for cholangiocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain FGF19 status and cholangiocarcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

FGF19 is an inclusion criterion in 2 clinical trials for hepatocellular carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FGF19 status and hepatocellular carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

FGF19 is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains FGF19 status and anaplastic astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

FGF19 is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains FGF19 status and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

FGF19 is an inclusion criterion in 1 clinical trial for cancer, of which 0 are open and 1 is closed. Of the trial that contains FGF19 status and cancer as inclusion criteria, 1 is phase 2 (0 open) [4].

FGF19 is an inclusion criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF19 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

FGF19 is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FGF19 status and esophageal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

FGF19 is an inclusion criterion in 1 clinical trial for extrahepatic cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF19 status and extrahepatic cholangiocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

FGF19 is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF19 status and gastric carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

FGF19 is an inclusion criterion in 1 clinical trial for glioblastoma, of which 1 is open and 0 are closed. Of the trial that contains FGF19 status and glioblastoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

FGF19 is an inclusion criterion in 1 clinical trial for intrahepatic cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF19 status and intrahepatic cholangiocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

FGF19 is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains FGF19 status and multiple myeloma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

FGF19 is an inclusion criterion in 1 clinical trial for myeloproliferative neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGF19 status and myeloproliferative neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

FGF19 is an inclusion criterion in 1 clinical trial for nasopharyngeal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FGF19 status and nasopharyngeal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

FGF19 is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FGF19 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

FGF19 is an inclusion criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF19 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].